Skip to main content
TipRanks
Go Ultimate75% OFF

Adherium Ltd. (ADR) AI Stock Analysis

38 Followers
AU:ADR

Adherium Ltd.

(ASX:ADR)

Select Model
Rating:37Underperform
Price Target:AUD 0.05â–¼(-2.08% Downside)
Action:reiterated
Date:10/24/26

Adherium Ltd. receives a minimum score due to extreme financial distress, including massive operational deficits and critical solvency risks. This precarious financial position is further compounded by a deeply negative valuation profile and severe bearish momentum across all major technical indicators.

Positive Factors
Digital respiratory health platformThe company operates in a structurally relevant digital-health niche by combining connected inhaler devices with software and actionable adherence data. This integrated model can support recurring use across providers, researchers, and life-sciences organizations while addressing persistent asthma and COPD management needs.
Negative Factors
Severe ongoing unprofitabilityLosses of this magnitude show that the company’s current cost structure is not scaling with sales, despite the revenue rebound and positive gross margin. Persistent operating deficits can consume capital, delay self-funding, and make durable profitability dependent on substantial improvement in expense discipline or revenue scale.

Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)

-80%-60%-40%-20%0%20%40%AU:ADR-74.74%EWA+14.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 924.89K
Dividend Yield
―
Average Volume (3M)
50.47K
Price to Earnings (P/E)
-0.1
Beta (1Y)
1.14
Revenue Growth
157.02%
EPS Growth
69.43%
Country
Australia
Employees
40
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Adherium Ltd. Business Overview & Revenue Model

Company Description

Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanni...

Adherium Ltd. Financial Statement Overview

Summary

The company faces critical solvency and liquidity risks, marked by massive net losses, a depleted balance sheet with negative equity, and an accelerating cash burn rate despite recent top-line growth.

Income Statement

15Very Negative

Balance Sheet

10Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue2.10M2.10M817.24K840.98K3.19M529.00K
Gross Profit1.22M1.22M111.37K267.70K1.69M-690.00K
EBITDA-14.36M-14.36M-12.44M-11.56M-11.50M-12.65M
Net Income-14.16M-14.16M-12.68M-10.22M-9.86M-10.04M
Balance Sheet
Total Assets4.56M4.56M3.52M9.89M12.68M8.53M
Cash, Cash Equivalents and Short-Term Investments1.42M1.42M43.26K6.20M9.08M5.28M
Total Debt2.40M2.40M3.12M93.20K44.00K85.00K
Total Liabilities5.85M5.85M8.28M3.41M3.47M3.00M
Stockholders Equity-1.29M-1.29M-4.76M6.48M9.21M5.54M
Cash Flow
Free Cash Flow-14.87M-14.87M-10.03M-10.61M-9.32M-9.89M
Operating Cash Flow-14.83M-14.83M-9.98M-10.61M-9.28M-9.61M
Investing Cash Flow-39.00K-39.00K-48.19K-37-41.00K-279.00K
Financing Cash Flow16.32M16.32M3.87M7.73M13.07M0

Adherium Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:ADR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:ALCAU:ALC69NeutralAUD 168.73M73.532.53%―26.61%38.21%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:AHEAU:AHE43NeutralAUD 8.29M-0.42-614.15%―-46.09%70.70%
AU:BMTAU:BMT40UnderperformAUD 20.08M-1.08-58.13%―2.08%-195.31%
AU:PCKAU:PCK38UnderperformAUD 14.23M-1.57-1688.04%―11.45%0.69%
AU:ADRAU:ADR37UnderperformAUD 2.74M-0.131363.47%―157.02%69.43%
AU:ICRAU:ICR37UnderperformAUD 12.16M-5.00-416.53%―113.42%29.17%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%AU:ADRAU:BMTAU:AHEAU:ALCAU:ICRAU:PCKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:ADR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:ADRAdherium Ltd.0.05-0.14-74.74%
AU:BMTBeamtree Holdings Ltd0.07-0.13-66.50%
AU:AHEMedAdvisor Limited0.01-0.01-38.10%
AU:ALCAlcidion Group Limited1.250.1513.64%
AU:ICRInteliCare Holdings Limited0.02-0.01-39.29%
AU:PCKPainChek Ltd0.07-0.33-82.96%

Adherium Ltd. Corporate Events

Adherium Secures Additional Funding from Barvest to Support Working Capital

Oct 30, 2026

Adherium Limited, a Melbourne-based digital health company, specialises in connected respiratory medical devices and the FDA-cleared Hailie Smartinhaler platform, which enables remote monitoring of medication use and adherence for patients with respi...

Adherium Sets 2026 AGM, Seeks Extra Placement Capacity and Board Changes

Oct 28, 2026

Adherium Limited has called its 2026 Annual General Meeting for 30 November, to be held virtually, with shareholders able to vote and submit questions online or by proxy under updated electronic communication rules. The meeting will consider the adop...

Adherium Expands U.S. Footprint With Florida Pulmonary Group Hailie Deal

Oct 25, 2026

Adherium has entered a partnership with Florida Lung, Asthma & Sleep Specialists, an independent pulmonary and critical care practice in Central Florida, to deploy its Hailie Smartinhaler platform across the group’s greater Orlando locations. The rol...

Adherium Secures Non-Dilutive AUD$700,000 Loan to Support Working Capital

Oct 6, 2026

Adherium Limited, a global provider of connected respiratory medical devices and digital health solutions, has built its Hailie platform to support remote monitoring of respiratory medication use. The system integrates sensors, mobile and desktop app...

Adherium Lodges Updated Corporate Governance Statement with ASX

Sep 30, 2026

Adherium Ltd has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX, confirming that the document is current as at 30 September 2026 and is available via the company’s investor website. The filing, accompanied by a...

Adherium Secures A$4.67m Term Loan from Major Shareholder Trudell

Sep 15, 2026

Adherium Limited, a global player in digital respiratory management and connected inhaler technology, has consolidated its recent funding arrangements from major shareholder Trudell Medical into a single unsecured term loan. The company’s solutions,...

Adherium Boosts U.S. Revenue but Loss Widens on Growth Investments

Aug 31, 2026

Adherium reported a 157% jump in revenue to $2.1 million for the year to 30 June 2026, driven by the successful launch of its remote patient monitoring program in the United States. Despite the revenue surge, the company’s net loss widened to $14.2 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026